Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells
Neuro-Oncology · 2023
DOI: 10.1093/neuonc/noad118 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, 2023. Verfasst von Philipp Karschnia und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Chimeric antigen receptor (CAR) T-cells targeting CD19 have been established as a leading engineered T-cell therapy for B-cell lymphomas; however, data for patients with central nervous system (CNS) involvement are limited.
Methods
We retrospectively report on CNS-specific toxicities, management, and CNS response of 45 consecutive CAR T-cell transfusions for patients with active CNS lymphoma at the Massachusetts General Hospital over a 5-year period.
Results
Our cohort includes 17 patients with primary CNS lymphoma (PCNSL; 1 patient with 2 CAR T-cell transfusions) and 27 patients with secondary CNS lymphoma (SCNSL). Mild ICANS (grade 1–2) was observed after 19/45 transfusions (42.2%) and severe immune effector cell-associated neurotoxicity syndrome (ICANS) (grade 3–4) after 7/45 transfusions (15.6%). A larger increase in C-reactive protein (CRP) levels and higher rates of ICANS were detected in SCNSL. Early fever and baseline C-reactive protein levels were associated with ICANS occurrence. CNS response was seen in 31 cases (68.9%), including a complete response of CNS disease in 18 cases (40.0%) which lasted for a median of 11.4 ± 4.5 months. Dexamethasone dose at time of lymphodepletion (but not at or after CAR T-cell transfusion) was associated with an increased risk for CNS progression (hazard ratios [HR] per mg/d: 1.16, P = .031). If bridging therapy was warranted, the use of ibrutinib translated into favorable CNS-progression-free survival (5 vs. 1 month, HR 0.28, CI 0.1–0.7; P = .010).
Conclusions
CAR T-cells exhibit promising antitumor effects and a favorable safety profile in CNS lymphoma. Further evaluation of the role of bridging regimens and corticosteroids is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurosurgery, Section for Neuro-Oncology, Ludwig-Maximilians-University, Munich, Germany.
- German Cancer Consortium (DKTK), Partner Site Munich, Germany.
- Department of Pathology, Division of Neuropathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Medicine III, Section for Cellular Immunotherapy, Ludwig-Maximilians-University, Munich, Germany.
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Philipp Karschnia, Justin T Jordan, Scott R Plotkin, Daniel P Cahill, Areej El-Jawahri, P Connor Johnson
Zitieren
APA
Karschnia, P., Arrillaga-Romany, I. C., Eichler, A., Forst, D. A., Gerstner, E., Jordan, J. T., Ly, I., Plotkin, S. R., Wang, N., Martinez-Lage, M., Winter, S. F., Tonn, J. C., Rejeski, K., von Baumgarten, L., Cahill, D. P., Nahed, B. V., Shankar, G. M., Abramson, J. S., Barnes, J. A., …, & Dietrich, J. (2023). Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro-Oncology. https://doi.org/10.1093/neuonc/noad118
Vancouver
Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, et al. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro-Oncology. 2023. doi:10.1093/neuonc/noad118
BibTeX
@article{Karschnia2023,
author = {Karschnia, Philipp and Arrillaga-Romany, Isabel C and Eichler, April and Forst, Deborah A and Gerstner, Elizabeth and Jordan, Justin T and Ly, Ina and Plotkin, Scott R and Wang, Nancy and Martinez-Lage, Maria and Winter, Sebastian F and Tonn, Joerg-Christian and Rejeski, Kai and von Baumgarten, Louisa and Cahill, Daniel P and Nahed, Brian V and Shankar, Ganesh M and Abramson, Jeremy S and Barnes, Jeffrey A and El-Jawahri, Areej and Hochberg, Ephraim P and Johnson, P Connor and Soumerai, Jacob D and Takvorian, Ronald W and Chen, Yi-Bin and Frigault, Matthew J and Dietrich, Jorg},
title = {Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells},
journal = {Neuro-Oncology},
year = {2023},
doi = {10.1093/neuonc/noad118}
}
EUVIMED